OTCMKTS:HPPIHedgePath Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding HedgePath Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.06 -0.01 (-14.06 %) (As of 07/9/2020 04:00 PM ET) Add Compare Share Today's Range$0.06Now: $0.06▼$0.0650-Day Range$0.04MA: $0.06▼$0.0952-Week Range$0.04Now: $0.06▼$0.32Volume2,000 shsAverage Volume2,232 shsMarket Capitalization$22.63 millionP/E RatioN/ADividend YieldN/ABeta-1.16 ProfileAdvanced ChartCompetitorsEarningsFinancialsInsider TradesHeadlinesSEC FilingsSocial Media HedgePath Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for patients with cancers and non-cancerous proliferation disorders in the United States. It primarily focuses on the development of therapies for skin, lung, and prostate cancers. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including stem cell maintenance, cell differentiation, tissue polarity, and cell proliferation. It also develops super bioavailability (SUBA)-itraconazole oral capsules for patients with basal cell carcinoma nevus syndrome. SUBA-Itraconazole is a patented itraconazole formulation that enhances the absorption of itraconazole to enhance the bioavailability of orally administered drugs that are poorly soluble. The company was founded in 1992 and is headquartered in Tampa, Florida. HedgePath Pharmaceuticals, Inc. is a subsidiary of Mayne Pharma Ventures Pty Ltd.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for HedgePath Pharmaceuticals. Previous Next 2.2 Community Rank Outperform VotesHedgePath Pharmaceuticals has received 162 “outperform” votes. (Add your “outperform” vote.)Underperform VotesHedgePath Pharmaceuticals has received 212 “underperform” votes. (Add your “underperform” vote.)Community SentimentHedgePath Pharmaceuticals has received 56.68% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about HedgePath Pharmaceuticals and other stocks. Vote “Outperform” if you believe HPPI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HPPI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldHedgePath Pharmaceuticals does not currently pay a dividend.Dividend GrowthHedgePath Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, HedgePath Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.80% of the stock of HedgePath Pharmaceuticals is held by insiders. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.44 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:HPPI Previous Symbol CUSIPN/A CIK1042418 Webwww.hedgepathpharma.com Phone813-509-2417Debt Debt-to-Equity RatioN/A Current Ratio6.76 Quick Ratio6.76Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-6.11Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-4,550,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-246.03%Miscellaneous Employees2 Outstanding Shares370,450,000Market Cap$22.63 million Next Earnings DateN/A OptionableNot Optionable OTC:HPPI Rates by TradingView Receive HPPI News and Ratings via Email Sign-up to receive the latest news and ratings for HPPI and its competitors with MarketBeat's FREE daily newsletter. HedgePath Pharmaceuticals (OTCMKTS:HPPI) Frequently Asked Questions How has HedgePath Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? HedgePath Pharmaceuticals' stock was trading at $0.0799 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HPPI stock has decreased by 23.5% and is now trading at $0.0611. View which stocks have been most impacted by Coronavirus. Has HedgePath Pharmaceuticals been receiving favorable news coverage? Headlines about HPPI stock have been trending negative on Thursday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. HedgePath Pharmaceuticals earned a media sentiment score of -2.3 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about HedgePath Pharmaceuticals. Who are some of HedgePath Pharmaceuticals' key competitors? Some companies that are related to HedgePath Pharmaceuticals include BIOQUAL (BIOQ), Bioanalytical Systems (BASI), AIkido Pharma (AIKI), Cleveland BioLabs (CBLI), Tenax Therapeutics (TENX), Geovax Labs (GOVX), Vitality Biopharma (VBIO), US Stem Cell (USRM), Protalex (PRTX), ALGAE TEC LTD/S (ALGXY) and Redpoint Bio (RPBC). View all competitors. What other stocks do shareholders of HedgePath Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other HedgePath Pharmaceuticals investors own include TransAtlantic Petroleum (TAT), Eaton (ETN), Diamond Offshore Drilling (DO), Correvio Pharma (CORV), Clorox (CLX), CIT Group (CIT), Bank of Montreal (BMO), Blue Sphere (BLSP), BJs Wholesale Club (BJ) and Alimentation Couche-Tard (ATD.B). Who are HedgePath Pharmaceuticals' key executives? HedgePath Pharmaceuticals' management team includes the following people: Mr. Nicholas Jon Virca, Pres & CEO (Age 73)Mr. Garrison J. Hasara CPA, CPA, CFO, Treasurer, Sec. & Chief Compliance Officer (Age 50) What is HedgePath Pharmaceuticals' stock symbol? HedgePath Pharmaceuticals trades on the OTCMKTS under the ticker symbol "HPPI." How do I buy shares of HedgePath Pharmaceuticals? Shares of HPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is HedgePath Pharmaceuticals' stock price today? One share of HPPI stock can currently be purchased for approximately $0.06. How big of a company is HedgePath Pharmaceuticals? HedgePath Pharmaceuticals has a market capitalization of $22.63 million. HedgePath Pharmaceuticals employs 2 workers across the globe. What is HedgePath Pharmaceuticals' official website? The official website for HedgePath Pharmaceuticals is www.hedgepathpharma.com. How can I contact HedgePath Pharmaceuticals? HedgePath Pharmaceuticals' mailing address is 4830 W. Kennedy Blvd. Suite 600, Tampa FL, 33609. The company can be reached via phone at 813-509-2417 or via email at [email protected] This page was last updated on 7/9/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
